Flagella of Tumor-Targeting Bacteria Trigger Local Hemorrhage to Reprogram Tumor-Associated Macrophages for Improved Antitumor Therapy.
artesunate
engineered bacteria
erythrocytes
flagella
tumor-associated macrophages
Journal
Advanced materials (Deerfield Beach, Fla.)
ISSN: 1521-4095
Titre abrégé: Adv Mater
Pays: Germany
ID NLM: 9885358
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
12
06
2023
received:
11
04
2023
medline:
22
9
2023
pubmed:
13
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Tumor-associated macrophages (TAMs) exhibit an immunosuppressive M2 phenotype and lead to failure of antitumor therapy. Infiltrated erythrocytes during hemorrhage are recognized as a promising strategy for polarizing TAMs. However, novel materials that precisely induce tumor hemorrhage without affecting normal coagulation still face challenges. Here, tumor-targeting bacteria (flhDC VNP) are genetically constructed to realize precise tumor hemorrhage. FlhDC VNP colonizes the tumor and overexpresses flagella during proliferation. The flagella promote the expression of tumor necrosis factor α, which induces local tumor hemorrhage. Infiltrated erythrocytes during the hemorrhage temporarily polarize macrophages to the M1 subtype. In the presence of artesunate, this short-lived polarization is transformed into a sustained polarization because artesunate and heme form a complex that continuously produces reactive oxygen species. Therefore, the flagella of active tumor-targeting bacteria may open up new strategies for reprogramming TAMs and improving antitumor therapy.
Identifiants
pubmed: 37310893
doi: 10.1002/adma.202303357
doi:
Substances chimiques
Artesunate
60W3249T9M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2303357Subventions
Organisme : Chinese Ministry of Science and Technology
ID : 2022YFC3401600
Organisme : National Natural Science Foundation of China
ID : 32171372
Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
a) O. Demaria, S. Cornen, M. Daeron, Y. Morel, R. Medzhitov, E. Vivier, Nature 2019, 574, 45;
b) I. Vitale, G. Manic, L. M. Coussens, G. Kroemer, L. Galluzzi, Cell Metab. 2019, 30, 36.
L. Cassetta, J. W. Pollard, Nat. Rev. Drug Discovery 2018, 17, 887.
C. B. Rodell, S. P. Arlauckas, M. F. Cuccarese, C. S. Garris, R. Li, M. S. Ahmed, R. H. Kohler, M. J. Pittet, R. Weissleder, Nat. Biomed. Eng. 2018, 2, 578.
A. Mantovani, P. Allavena, F. Marchesi, C. Garlanda, Nat. Rev. Drug Discovery 2022, 21, 799.
a) F. Vinchi, M. Costa da Silva, G. Ingoglia, S. Petrillo, N. Brinkman, A. Zuercher, A. Cerwenka, E. Tolosano, M. U. Muckenthaler, Blood 2016, 127, 473;
b) M. T. Bozza, V. Jeney, Front. Immunol. 2020, 11, 1323;
c) F. F. Dutra, M. T. Bozza, Front. Pharmacol. 2014, 5, 115.
a) G. M. Tozer, C. Kanthou, B. C. Baguley, Nat. Rev. Cancer 2005, 5, 423;
b) R. E. Scharf, Semin. Thromb. Hemostasis 2012, 38, 865.
a) Y. Zhu, X. Wang, Y. Yang, L. Liu, Q. Zhao, L. Yu, Trials 2022, 23, 569;
b) J. H. Gill, K. L. Rockley, C. De Santis, A. K. Mohamed, Pharmacol. Ther. 2019, 202, 18.
S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak, W. C. W. Chan, Nat. Rev. Mater. 2016, 1, 16014.
C. R. Gurbatri, N. Arpaia, T. Danino, Science 2022, 378, 858.
a) J.-M. J. N. i. Reichhart, Nat. Immunol. 2003, 4, 1159;
b) J. Chen, Y. Qiao, G. Chen, C. Chang, H. Dong, B. Tang, X. Cheng, X. Liu, Z. Hua, Acta Pharm. Sin. B 2021, 11, 3165;
c) F. Ciacci-Woolwine, I. C. Blomfield, S. H. Richardson, S. B. J. I. Mizel, Infect. Immun. 1998, 66, 1127;
d) D. S. O'Mahony, U. Pham, R. Iyer, T. R. Hawn, W. C. Liles, Int. J. Med. Sci. 2008, 5, 1.
G. Canesin, S. M. Hejazi, K. D. Swanson, B. Wegiel, Front. Immunol. 2020, 11, 66.
J. Wang, C. J. Zhang, W. N. Chia, C. C. Loh, Z. Li, Y. M. Lee, Y. He, L. X. Yuan, T. K. Lim, M. Liu, C. X. Liew, Y. Q. Lee, J. Zhang, N. Lu, C. T. Lim, Z. C. Hua, B. Liu, H. M. Shen, K. S. Tan, Q. Lin, Nat. Commun. 2015, 6, 10111.
F. F. Chevance, K. T. Hughes, Nat. Rev. Microbiol. 2008, 6, 455.
J. Tan, X. Zhang, X. Wang, C. Xu, S. Chang, H. Wu, T. Wang, H. Liang, H. Gao, Y. Zhou, Y. Zhu, Cell 2021, 184, 2665.
X. Huang, J. Pan, F. Xu, B. Shao, Y. Wang, X. Guo, S. Zhou, Adv. Sci. 2021, 8, 2003572.
V. Raman, N. Van Dessel, C. L. Hall, V. E. Wetherby, S. A. Whitney, E. L. Kolewe, S. M. K. Bloom, A. Sharma, J. A. Hardy, M. Bollen, A. Van Eynde, N. S. Forbes, Nat. Commun. 2021, 12, 6116.
S. Nakamura, T. Minamino, Biomolecules 2019, 9, 279.
C. White, X. Yuan, P. J. Schmidt, E. Bresciani, T. K. Samuel, D. Campagna, C. Hall, K. Bishop, M. L. Calicchio, A. Lapierre, D. M. Ward, P. Liu, M. D. Fleming, I. Hamza, Cell Metab. 2013, 17, 261.
A. Robert, C. Bonduelle, S. A. L. Laurent, B. Meunier, J. Phys. Org. Chem. 2006, 19, 562.
S.-x. Chen, Peter Schopfer, Eur. J. Biochem. 1999, 260, 726.
a) Y. Xia, Y. Li, X. Wu, Q. Zhang, S. Chen, X. Ma, M. Yu, Front. Immunol. 2021, 12, 669566;
b) Y. Liu, Y. Wang, C. Wang, T. Dong, H. Xu, Y. Guo, X. Zhao, Y. Hu, J. Wu, Adv. Sci. 2022, 9, 2203027.
G. Hu, M. Guo, J. Xu, F. Wu, J. Fan, Q. Huang, G. Yang, Z. Lv, X. Wang, Y. Jin, Front. Immunol. 2019, 10, 1998.
R. Humar, D. J. Schaer, F. Vallelian, Trends Mol. Med. 2022, 28, 906.
H. Helmbach, E. Rossmann, M. A. Kern, D. Schadendorf, Int. J. Cancer 2001, 93, 617.
a) W. Wang, H. Xu, Q. Ye, F. Tao, I. Wheeldon, A. Yuan, Y. Hu, J. Wu, Nat. Biomed. Eng. 2022, 6, 44;
b) H. Xu, Y. Hu, J. Wu, Microb. Cell 2022, 9, 158.
S. Zhou, C. Gravekamp, D. Bermudes, K. Liu, Nat. Rev. Cancer 2018, 18, 727.
Z. Feng, Y. Wang, H. Xu, Y. Guo, W. Xia, C. Zhao, X. Zhao, J. Wu, Acta Pharm. Sin. B 2022, 13, 1014.
K. K. S. Lloren, V. Jawalagatti, C. Hewawaduge, C. Sivasankar, J.-Y. Park, J. H. J. M. Lee, Microbes Infect. 2023, 105101.